EA200200270A1 - Новые спиросоединения - Google Patents

Новые спиросоединения

Info

Publication number
EA200200270A1
EA200200270A1 EA200200270A EA200200270A EA200200270A1 EA 200200270 A1 EA200200270 A1 EA 200200270A1 EA 200200270 A EA200200270 A EA 200200270A EA 200200270 A EA200200270 A EA 200200270A EA 200200270 A1 EA200200270 A1 EA 200200270A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
compounds
group
optionally substituted
npy
Prior art date
Application number
EA200200270A
Other languages
English (en)
Other versions
EA004507B1 (ru
Inventor
Такехиро Фуками
Акио Канатани
Акане Исихара
Ясуюки Исии
Тосиюки Такахаси
Юдзи Хага
Тосихиро Сакамото
Такахиро Итох
Original Assignee
Баниу Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Баниу Фармасьютикал Ко., Лтд. filed Critical Баниу Фармасьютикал Ко., Лтд.
Publication of EA200200270A1 publication Critical patent/EA200200270A1/ru
Publication of EA004507B1 publication Critical patent/EA004507B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Настоящее изобретение касается соединений общей формулы (I)где Arпредставляет арил или гетероарил;n равно 0 или 1;Т, U, V и W независимо представляют атом азота или необязательно замещенную метиновую группу, причем, по меньшей мере, два из них представляют указанную метиновую группу;Х представляет метин или азот;Y представляет необязательно замещенную иминогруппу или атом кислорода; и подобных.Соединения настоящего изобретения демонстрируют NPY-антагонистические активности и полезны в качестве агентов для лечения различных заболеваний, связанных с NPY, например сердечно-сосудистых нарушений, таких как гипертензия, нефропатия, болезнь сердца, вазоспазм, артериосклероз и подобные, нарушений центральной нервной системы, таких как булемия, депрессия, тревога, припадок, эпилепсия, слабоумие, боль, алкоголизм, синдром отмены наркотика и подобные, нарушений обмена веществ, таких как ожирение, диабет, гормональное нарушение, гиперхолестеринемия, гиперлипидемия и подобные, сексуальной и репродуктивной дисфункции, желудочно-кишечных заболеваний, респираторных заболеваний, воспаления или глаукомы и подобных.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200270A 1999-08-20 2000-08-11 Новые спиросоединения EA004507B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23357399 1999-08-20
JP2000137692 2000-05-10
PCT/JP2000/005427 WO2001014376A1 (en) 1999-08-20 2000-08-11 Novel spiro compounds

Publications (2)

Publication Number Publication Date
EA200200270A1 true EA200200270A1 (ru) 2002-08-29
EA004507B1 EA004507B1 (ru) 2004-04-29

Family

ID=26531087

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200270A EA004507B1 (ru) 1999-08-20 2000-08-11 Новые спиросоединения

Country Status (36)

Country Link
US (3) US6326375B1 (ru)
EP (1) EP1204663B1 (ru)
KR (1) KR100749713B1 (ru)
CN (2) CN100457757C (ru)
AR (1) AR029000A1 (ru)
AT (1) ATE253064T1 (ru)
AU (1) AU767229B2 (ru)
BG (1) BG65805B1 (ru)
BR (1) BR0013423A (ru)
CA (1) CA2379103C (ru)
CO (1) CO5200768A1 (ru)
CZ (1) CZ2002533A3 (ru)
DE (1) DE60006251T2 (ru)
DK (1) DK1204663T3 (ru)
DZ (1) DZ3175A1 (ru)
EA (1) EA004507B1 (ru)
EE (1) EE05248B1 (ru)
ES (1) ES2206287T3 (ru)
GE (1) GEP20053488B (ru)
HK (1) HK1043123B (ru)
HR (1) HRP20020102B1 (ru)
HU (1) HUP0203107A3 (ru)
IL (1) IL148119A0 (ru)
IS (1) IS2420B (ru)
MX (1) MXPA02001693A (ru)
MY (1) MY130769A (ru)
NO (1) NO323514B1 (ru)
NZ (1) NZ517057A (ru)
PE (1) PE20010645A1 (ru)
PL (1) PL353743A1 (ru)
PT (1) PT1204663E (ru)
RS (1) RS50484B (ru)
SK (1) SK286609B6 (ru)
TR (1) TR200200408T2 (ru)
TW (1) TWI279402B (ru)
WO (1) WO2001014376A1 (ru)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
US6462053B1 (en) * 1999-08-20 2002-10-08 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US6803372B2 (en) * 1999-08-20 2004-10-12 Banyu Pharmaceutical Co., Ltd. Spiro compounds
WO2002028393A1 (en) * 2000-10-03 2002-04-11 The Regents Of The University Of California Use of neuropeptide-y antagonists in treatment of alcoholism
ATE310004T1 (de) * 2000-12-12 2005-12-15 Neurogen Corp Spiro(isobenzofuran-1,4'-piperidin)-3-one und 3h- spiroisobenzofuran-1,4'-piperidine
EP1695977A3 (en) * 2000-12-12 2006-09-20 Neurogen Corporation Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines
US6946476B2 (en) 2000-12-21 2005-09-20 Schering Corporation Heteroaryl urea neuropeptide Y Y5 receptor antagonists
EP1343503B1 (en) 2000-12-21 2008-11-12 Schering Corporation Heteroaryl urea neuropeptide y y5 receptor antagonists
US6924291B2 (en) 2001-01-23 2005-08-02 Merck & Co., Inc. Process for making spiro isobenzofuranone compounds
WO2002094825A1 (fr) * 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
WO2003010175A2 (en) * 2001-07-24 2003-02-06 Merck & Co., Inc. Radiolabeled neuropeptide y y5 receptor antagonists
US7205417B2 (en) * 2001-08-07 2007-04-17 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US20050107411A1 (en) * 2001-12-17 2005-05-19 Macneil Douglas J. Method for treating circadian rhythm disruptions
AU2002359706A1 (en) * 2001-12-17 2003-06-30 Merck And Co., Inc. Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia
US6605720B1 (en) 2002-01-28 2003-08-12 Merck & Co., Inc. Process for making spirolactone compounds
WO2003077847A2 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
EP1532147B1 (en) 2002-06-27 2006-08-02 Schering Corporation Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
MXPA05000200A (es) * 2002-07-02 2005-06-06 Schering Corp Nuevos antagonistas del receptor neuropeptido y y5.
US20050288213A1 (en) * 2002-07-18 2005-12-29 Macneil Douglas J Combination therapy for the treatment of obesity
JP2006503101A (ja) * 2002-10-18 2006-01-26 メルク　エンド　カムパニー　インコーポレーテッド スピロラクトン化合物の製造方法
AU2003302640B2 (en) 2002-11-29 2009-09-24 Banyu Pharmaceutical Co., Ltd. Novel azole derivatives
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
AU2003290323A1 (en) * 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AR044283A1 (es) * 2003-05-19 2005-09-07 Merck & Co Inc Procedimeinto para preparar compuestos de espirolactona
EP1635773A2 (en) * 2003-06-06 2006-03-22 Merck & Co., Inc. (a New Jersey corp.) Combination therapy for the treatment of hypertension
WO2004110375A2 (en) * 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of diabetes
US20060148721A1 (en) * 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
US20050069244A1 (en) * 2003-09-25 2005-03-31 Miguel Dajer Flexible distributed wireless signal system and method
CA2540197A1 (en) * 2003-09-26 2005-04-07 Pfizer Products Inc. Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists
MXPA06003380A (es) * 2003-09-26 2006-06-08 Pfizer Prod Inc Uso de antagonista del receptor npy y5 para el tratamiento de trastornos del ritmo circadiano.
CN1938286A (zh) 2004-03-29 2007-03-28 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的二芳基三唑
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
BRPI0510273A (pt) 2004-05-25 2007-10-30 Pfizer Prod Inc derivados de tetraazabenzo[e]azuleno e análogos destes
CA2575736A1 (en) 2004-08-06 2006-02-16 Merck & Co., Inc. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP2364705A3 (en) 2004-08-19 2012-04-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP5135795B2 (ja) 2004-08-27 2013-02-06 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
EP1795527B1 (en) * 2004-09-07 2009-04-22 Banyu Pharmaceutical Co., Ltd. Carbamoyl-substituted spiro derivative
WO2006052608A2 (en) * 2004-11-01 2006-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CN101155587A (zh) 2004-11-29 2008-04-02 弗特克斯药品有限公司 毒蕈碱受体调节剂
MX2007008957A (es) * 2005-01-25 2007-12-06 Synta Pharmaceuticals Corp Compuestos para usos relacionados a inflamacion de inmunidad.
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060270650A1 (en) * 2005-05-26 2006-11-30 Macneil Tanya Combination therapy for the treatment of obesity
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
EP1912642B1 (en) 2005-07-28 2012-10-17 Merck Sharp & Dohme Corp. A crystalline form of a npy5 antagonist
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7875633B2 (en) 2005-08-24 2011-01-25 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
JP2009507800A (ja) * 2005-09-09 2009-02-26 ユーロ−セルティーク エス．エイ． 縮合およびスピロ環化合物ならびにその使用
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
AU2006312557B2 (en) * 2005-11-10 2011-12-08 Msd K.K. Aza-substituted spiro derivative
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
KR20080087841A (ko) * 2005-12-22 2008-10-01 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체의 조절제
AU2007221214A1 (en) * 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
KR20080098070A (ko) * 2006-02-22 2008-11-06 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘
DE602007008545D1 (de) 2006-03-31 2010-09-30 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
AU2007269863A1 (en) * 2006-06-29 2008-01-10 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2051712A2 (en) * 2006-08-15 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
US7786107B2 (en) * 2006-08-18 2010-08-31 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
BRPI0720004A2 (pt) * 2006-12-07 2013-12-17 Hoffmann La Roche Derivados de espiro-piperidina como antagonista de receptor v1a
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
KR101122969B1 (ko) * 2006-12-22 2012-03-22 에프. 호프만-라 로슈 아게 스피로-피페리딘 유도체
BRPI0721138A2 (pt) 2006-12-22 2014-04-01 Hoffmann La Roche Derivados de espiro-piperidina
EP2125827B1 (en) * 2006-12-29 2010-11-03 F. Hoffmann-La Roche AG Azaspiro derivatives
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2010003373A (es) * 2007-10-03 2010-04-30 Vertex Pharma Moduladores de receptores muscarinicos.
US20100323955A1 (en) * 2007-11-14 2010-12-23 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
EP2225248A1 (en) * 2007-11-30 2010-09-08 Wyeth LLC Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
CN102014900B (zh) * 2008-03-11 2014-04-02 大学健康网络 一种神经肽y5r(npy5r)拮抗剂在制备治疗癌症的药物中的应用
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2727914A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8592457B2 (en) 2008-10-30 2013-11-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2010058318A1 (en) * 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
TW201111383A (en) 2009-05-29 2011-04-01 Wyeth Llc Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
JP2013510834A (ja) 2009-11-16 2013-03-28 メリテク ［１，５］‐ジアゾシン誘導体
EP2521721B1 (en) 2009-12-30 2014-10-01 Shanghai Fochon Pharmaceutical Co. Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
WO2011156246A1 (en) 2010-06-11 2011-12-15 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
PE20140859A1 (es) 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
BR112015002080A2 (pt) 2012-08-02 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme BICYCLIC ANTIDIABETIC COMPOUNDS
EP3660011A1 (en) 2013-03-06 2020-06-03 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US10076698B2 (en) 2016-05-17 2018-09-18 Sportsmedia Technology Corporation Automated or assisted umpiring of baseball game using computer vision
TWI767945B (zh) 2016-10-14 2022-06-21 義大利商Ｔｅｓ製藥（股份）責任有限公司 α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
SG11202104550WA (en) 2018-11-20 2021-05-28 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4200295A1 (en) 2020-08-18 2023-06-28 Merck Sharp & Dohme LLC Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2168512C2 (ru) * 1992-12-11 2001-06-10 Мерк Энд Ко., Инк. Спиропиперидины, способы их получения (варианты)
US6166209A (en) * 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
AU756797B2 (en) * 1998-11-10 2003-01-23 Banyu Pharmaceutical Co., Ltd. Spiro-indolines as Y5 receptor antagonists

Also Published As

Publication number Publication date
HRP20020102A2 (en) 2004-02-29
TWI279402B (en) 2007-04-21
HRP20020102B1 (en) 2005-04-30
RS50484B (sr) 2010-03-02
PL353743A1 (en) 2003-12-01
KR20020021410A (ko) 2002-03-20
MXPA02001693A (es) 2002-08-06
CN100457757C (zh) 2009-02-04
CA2379103A1 (en) 2001-03-01
BR0013423A (pt) 2002-05-07
WO2001014376A1 (en) 2001-03-01
US20020052371A1 (en) 2002-05-02
IS2420B (is) 2008-10-15
CZ2002533A3 (cs) 2002-08-14
SK286609B6 (sk) 2009-02-05
IS6267A (is) 2002-02-13
IL148119A0 (en) 2002-09-12
HUP0203107A3 (en) 2004-06-28
US6388077B1 (en) 2002-05-14
DK1204663T3 (da) 2004-02-09
AU6476200A (en) 2001-03-19
HK1043123A1 (en) 2002-09-06
AU767229B2 (en) 2003-11-06
GEP20053488B (en) 2005-04-25
EP1204663A1 (en) 2002-05-15
EA004507B1 (ru) 2004-04-29
HK1043123B (zh) 2004-01-30
ATE253064T1 (de) 2003-11-15
PT1204663E (pt) 2004-02-27
EP1204663B1 (en) 2003-10-29
AR029000A1 (es) 2003-06-04
BG106390A (en) 2002-12-29
CN1640877A (zh) 2005-07-20
ES2206287T3 (es) 2004-05-16
NO20020814D0 (no) 2002-02-19
PE20010645A1 (es) 2001-06-07
CO5200768A1 (es) 2002-09-27
BG65805B1 (bg) 2009-12-31
US6326375B1 (en) 2001-12-04
NO323514B1 (no) 2007-06-04
EE05248B1 (et) 2009-12-15
CN1370168A (zh) 2002-09-18
DE60006251D1 (de) 2003-12-04
CN1202108C (zh) 2005-05-18
HUP0203107A2 (hu) 2002-12-28
NO20020814L (no) 2002-04-15
US6335345B1 (en) 2002-01-01
EE200200082A (et) 2003-06-16
YU10802A (sh) 2004-09-03
DZ3175A1 (fr) 2001-03-01
MY130769A (en) 2007-07-31
TR200200408T2 (tr) 2002-06-21
CA2379103C (en) 2010-06-15
DE60006251T2 (de) 2004-05-13
NZ517057A (en) 2003-08-29
KR100749713B1 (ko) 2007-08-16
SK2522002A3 (en) 2002-08-06
WO2001014376A8 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
EA200200270A1 (ru) Новые спиросоединения
EA200400288A1 (ru) Спиросоединения
ATE292119T1 (de) Imidazolin-verbindungen
KR0179661B1 (ko) N-페닐알킬 치환된 알파-아미노 카복스아미드 유도체 및 이를 포함하는 약제학적 조성물 및 이의 제조방법
NZ501849A (en) Carbonyl hydrazino derivatives further substituted by carbamate or sulphonamide groups
ATE374194T1 (de) Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
DE60221098D1 (de) Kondensierte heterocyclische derivate
DE69826151D1 (de) 1-substituierte-1-aminomethyl-cycloalkan derivate (= gabapentin analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen
WO2004033422A3 (en) Modulation of anxiety through blockade of anandamide hydrolysis
MX2010006182A (es) Derivados de isoxazolo-piridazina.
CA2469813A1 (en) Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
NZ507763A (en) N-substituted aminotetralin sulphonamide derivatives useful as ligands for the neuropeptide Y Y5 receptor used in the treatment of obesity and other disorders
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
WO2004089306A3 (en) Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
JO2425B1 (en) Method for manufacturing vinyl acetate acid derivatives
EA199800738A1 (ru) Производные бензопирана, обладающие антагонистическим действием в отношении лейкотриена
DK0976745T3 (da) 4-tetrahydropyridylpyrimidinderivat
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
CA2291620A1 (en) Production method of isoxazolidinedione compound
EP1591441A4 (en) CARBON ACID COMPOUNDS
ATE304016T1 (de) Antidepressive (sssri) azaheterocyclylmethylderivate von 7,8-dihydro-3h- 6,9-dioxa-1,3-diazacyclopenta (a) naphthalin
RU2006141835A (ru) Тетразамещенные производные имидазола в качестве модуляторов рецепторов св1 каннабиноидов с высокой селективностью к подтипам рецепторов св1/св2
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung
DE60224509D1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
EA200200733A1 (ru) Новые гетероарильные производные, их получение и применение

Legal Events

Date Code Title Description
NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU